Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.

Autor: Yamaba, Shinpei1 (AUTHOR), Imai, Yukinori1 (AUTHOR), Sugawara, Kayoko1 (AUTHOR), Uchida, Yoshihito1 (AUTHOR), Fuchigami, Akira1 (AUTHOR), Uchiya, Hiroshi1 (AUTHOR), Nakayama, Nobuaki1 (AUTHOR), Mochida, Satoshi1 (AUTHOR) smochida@saitama-med.ac.jp
Zdroj: PLoS ONE. 4/30/2024, Vol. 19 Issue 4, p1-16. 16p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje